We recently gathered as a team in New York. The opportunity to connect in person strengthened collaboration across our teams and reinforced the shared commitment behind the work we do advancing novel therapies for neuropsychiatric disorders. Learn more: https://t.co/7tpnoLYTDK
Bipolar disorder affects an estimated 2.8% of Americans and remains a significant burden. We are advancing LB-102, an investigational therapy for #BipolarDepression, in a recently initiated Phase 2 trial. Learn more: https://t.co/s28AUVLYEi
Bold innovation requires purpose-driven people. In our new #LBBold series, we'll highlight the talented minds behind LB Pharma. Our Senior Director of Corporate Administration, Lauren Stipp, plays an important role in our success. Learn about our team: https://t.co/A9x2sYgDOq
James Rawls, Pharm.D., joins us as SVP, Regulatory Affairs. His FDA & global CNS regulatory experience make him a great addition to our team as we aim to advance LB-102 as a potential treatment for neuropsychiatric disorders in the US: https://t.co/NEATijm6af
We celebrated our IPO by ringing the @Nasdaq Closing Bell! This milestone reflects our commitment to advancing our investigational therapy, LB-102, for neuropsychiatric disorders. Thanks to all who made our IPO possible! Watch here: https://t.co/pQ0FoaszPj $LBRX
Gad Soffer joins as CBO and Richard Silva, Ph.D., as SVP of Technical Operations! Their expertise in business strategy, CMC & manufacturing will be key in advancing LB-102 to potentially bring safer treatments to patients with #schizophrenia. Read more: https://t.co/EMMpjYAvZ5
Our leadership team had a great week at #JPM25. They presented our new Phase 2 data in #schizophrenia and connected with peers, collaborators, and investors. We are excited for another year of pushing boundaries as we work to develop new #psychiatric treatments.
Our CEO, Heather Turner, is joining industry peers in a panel discussion at #JPM25 where participants will discuss the critical role of women's leadership in biotech.
Today we shared topline data from the Phase 2 #ClinicalTrial of our potential treatment for #schizophrenia. Data indicate that the primary endpoint was met with statistically significant reductions in PANNS total score vs. placebo at all doses. More here: https://t.co/tLjUfKla8L
Join our CEO, Heather Turner, for a corporate presentation at #JPM25. We're looking forward to discussing the latest updates from LB Pharma as we connect with industry peers and investors. Read more here: https://t.co/gj8U0H8woy
LB Pharmaceuticals Announces Publication of Phase 1 Clinical Study of LB-102
"This clinical study enrolled 64 healthy volunteers and was the first time LB-102 had been dosed in humans..."
https://t.co/oJFvXiCJMB
@News12LI I hope it helps! I've walked that trail with my dog many times, mostly during the fall. We tried once last summer and she was covered head to toe with ticks. Go quails!
We are excited to announce the launch of our varsity Unified Basketball Team sponsored by the Special Olympics!
Be sure to support the team at its first home game on May 10 at 5 p.m.🏀
@travelocity@TravelocityHelp This is a joke right? Been using Travelocity for years & access to customer service has completely gone downhill. Agents unavailable by chat or phone. Currently on hold for over 2 hours now. This is SIMPLY to ask a question about a credit that apparently I can't use. Awful!!